News | May 27, 2023
Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Agasta Software is engaged in research, development and commercialization of medical devices
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
Subscribe To Our Newsletter & Stay Updated
